

INTERACTIONS

Increase: hypotension—antihypertensives, separate by 12 hr

Increase: nephrotoxicity—CISplatin, avoid concurrent use; if used, monitor renal status

Increase: bleeding—anticoagulant

- Avoid with vaccines, toxoids

NURSING CONSIDERATIONS

Assess:

Black Box Warning: Fatal infusion reaction: hypoxia, pulmonary infiltrates, ARDS, MI, ventricular fibrillation, cardiogenic shock; most fatal reactions occur with 1st infusion; potentially fatal

Black Box Warning: Severe mucocutaneous reactions: Stevens-Johnson syndrome, lichenoid dermatitis, toxic epidermal lysis; occur 1-13 wk after product given, discontinue treatment immediately

Black Box Warning: Tumor lysis syndrome: acute renal failure requiring hemodialysis, hyperkalemia, hypocalcemia, hyperuricemia, hyperphosphatemia; allopurinol and adequate hydration may be needed

Black Box Warning: Multifocal leukoencephalopathy: confusion, dizziness, lethargy, hemiparesis; monitor periodically

• **Bone marrow suppression:** CBC, differential, platelet count weekly; withhold product if WBC is $<3500/\text{mm}^3$ or platelet count $<100,000/\text{mm}^3$; notify prescriber of results; product should be discontinued

• ECG, serum creatinine/BUN, electrolytes, uric acid; correct electrolyte imbalances before use; hyperkalemia, hypocalcemia, hyperphosphatemia often occur

• GI symptoms: frequency of stools, abdominal pain, perforation/obstruction may occur

• **Infection:** fever, increased temperature, flulike symptoms in those with Wegener's granulomatosis and microscopic polyangiitis in those using DMARDs

Black Box Warning: Hepatitis B exacerbation: fulminant hepatitis, hepatic failure, death may occur during or following treatment; screen all patients for HBV infection (HBV/HBsAg and anti-HB_c titers) before use; monitor those with current or prior HBV for signs of hepatitis or for HBV reactivation for several months after therapy; if reactivation occurs, discontinue product

• **Pregnancy/breastfeeding:** use only if benefits outweigh fetal risk; contraception should be used; enroll pregnant women in the Mother To Baby Autoimmune Diseases in Pregnancy Study, 1-877-311-8972 (patients with RA); do not breastfeed, excretion unknown

Evaluate:

• Therapeutic response: prevention of increasing cancer progression

Teach patient/family:

- To avoid use with vaccines, toxoids
- To use contraception during and for up to 12 mo after therapy
- To report to prescriber possible infection (cough, fever, chills, sore throat), renal issues (painful urination, back/side pain), bleeding (gums, stools, urine, bruising, emesis, fatigue)
- To avoid OTC products
- To avoid crowds, those with known infections
- To increase fluid intake

HIGH ALERT

rivaroxaban

Xarelto

Func. class.: Anticoagulant

Chem. class.: Factor Xa inhibitor

ACTION: A novel oral anticoagulant that selectively and potently inhibits coagulation factor Xa